Antisense oligodeoxynucleotides for the treatment of chronic myelogenous leukemia: are they still a promise?
de Fabritiis
P
P
Calabretta
B
B
D000818:Animals; D016465:Bone Marrow Purging; D016026:Bone Marrow Transplantation; D002986:Clinical Trials as Topic; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000235:genetics; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects*; D015316:Genetic Therapy; D006801:Humans; D007942:Leukemia, Experimental / Q000628:therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000628:therapy*; D051379:Mice; D016513:Mice, SCID; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000235:genetics; D016376:Oligonucleotides, Antisense / Q000494:pharmacology / Q000627:therapeutic use*; D010865:Pilot Projects; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000235:genetics; D020598:Proto-Oncogene Proteins c-myb; D013873:Thionucleotides / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
D009363:Neoplasm Proteins; D016376:Oligonucleotides, Antisense; D011518:Proto-Oncogene Proteins; D020598:Proto-Oncogene Proteins c-myb; D013873:Thionucleotides; D016044:Fusion Proteins, bcr-abl